title: Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis.
authors.affiliation: Kinki University Faculty of Medicine, Osaka, Japan.
authors.forename: Hisato
authors.initials: H
authors.lastname: Kawakami
authors.forename: Koji
authors.initials: K
authors.lastname: Sugioka
authors.forename: Kimio
authors.initials: K
authors.lastname: Yonesaka
authors.forename: Taroh
authors.initials: T
authors.lastname: Satoh
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Shimomura
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Nakagawa
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000473:pathology; D004815:Epidermal Growth Factor / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D000077146:Irinotecan; D007634:Keratitis / Q000139:chemically induced / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000556:secondary; D009883:Ophthalmic Solutions
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D009883:Ophthalmic Solutions; D004815:Epidermal Growth Factor; D000077146:Irinotecan; D000068818:Cetuximab; D002166:Camptothecin